



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 29th May, 2024.

To,
Department of Corporate Service (DCS-CRD),
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.
SCRIP CODE: 526490

Subject: Outcome of Board Meeting held on 29th May, 2024 pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref.: NORRIS MEDICINES LIMITED Script Code: 524414.

Dear Sir,

With reference to above captioned subject, we hereby inform you that the Board of Directors in their Meeting held on 29th May, 2024 commenced at 6.00 p.m. inter alia has: -

1. Approval of Audited Standalone Financial Results for the quarter and year ended March 31, 2024 as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
2. Approval of statement of Assets and liabilities for the year ended March 31, 2024.
3. Also note that M/s.Bahedia & Associates, Statutory auditors of the Company have issued the Audit report for the financial year ended on March 31, 2024 with unmodified opinion pursuant to regulation 33(3)(d) of the SEBI(LODR), Regulations, 2015.

The meeting was commenced on 6.00 p.m. and concluded at 7.15 p.m.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You,
Yours truly,
For NORRIS MEDICINES LTD

Name: VIMAL DHIRENDRA SHAH
DIN: 01506655
Designation: Director